Symptomatic Resolution Among Chinese Patients With Schizophrenia and Associated Factors  by Li, Cheng-Ta et al.
378 J Formos Med Assoc | 2010 • Vol 109 • No 5
Contents lists available at ScienceDirect
Journal of the Formosan Medical Association
Journal homepage: http://www.jfma-online.com
J Formos Med Assoc 2010;109(5):378–388
Journal of the 
Formosan Medical Association
ISSN 0929 6646
Formosan Medical Association
Taipei, Taiwan
Volume 109 Number 5 May 2010
Clinical implications of HBV variants
GRP78 protein as a biomarker of oral cancer in Taiwan
Pemetrexed in heavily pretreated patients with advanced NSCLC
Sex differences in geriatric depression
Original Article
Symptomatic Resolution Among Chinese Patients
With Schizophrenia and Associated Factors
Cheng-Ta Li,1,2 Tung-Ping Su,1,2 Yuan-Hwa Chou,1,2 Ying-Chiao Lee,1,2 Mu-En Liu,1
Hsiao-Lun Ku,1 Ian-Kai Shan,1 Ya-Mei Bai1,2*
Background/Purpose: The remission and resolution criteria for schizophrenia were defined by the
Remission in Schizophrenia Working Group in 2005, using eight core items of the positive and negative
symptoms scale for schizophrenia. Subsequent studies of Caucasians have reported similar remission/res-
olution rates of approximately one-third. However, the remission/resolution rate in Chinese patients has
not previously been reported. The present study assessed symptom resolution rates and associated factors
among medicated and clinically stable Chinese schizophrenia patients.
Methods: Chinese patients with a diagnosis of schizophrenia were followed-up 1 month after their last
psychiatric hospitalization. Cross-sectional clinical assessments for psychopathology, side effect profiles,
quality of life, psychosocial function, and neurocognition tests were performed.
Results: Thirty-three (36.7%) of a total of 90 patients met the resolution criteria. They had a significantly
higher level of education and lower scores for positive symptoms, negative symptoms, and general psy-
chopathology on the positive and negative symptoms scale; they had lower scores on the Udvalg for
Kliniske Undersøgelser Side Effect Rating Scale, and Simpson Angus Scale; and higher scores on the Global
Assessment of Functioning and Subjective Well-being under Neuroleptics scales, compared with patients
who did not meet the resolution criteria. Multiple regression analyses controlling for age, sex, duration of
illness, education, duration of index hospitalization, and antipsychotic dosage revealed that a higher
Udvalg for Kliniske Undersøgelser Side Effect Rating Scale score was related to lower rate of symptom res-
olution. The patients treated with clozapine and combinations of first generation antipsychotics and sec-
ond generation antipsychotics had more severe psychopathology and side effects and showed a significantly
lower resolution rate than did patients treated with first generation antipsychotics or second generation
antipsychotics alone.
Conclusion: Consistent with studies of Caucasian patients, one-third of clinically stable Chinese patients
met the resolution criteria, as well as having fewer general side effects, better global functioning and 
subjective well-being.
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Schizophrenia is regarded as a chronic illness with
a worse outcome than other psychotic disorders,1
but there is still a proportion of patients who have
better outcomes. Many researchers have tried to
define remission criteria for schizophrenia using
divergent thresholds of symptom severity and dif-
ferent ratings scales and duration criteria.2–6 This
has made comparison between studies and under-
standing of remission in schizophrenia difficult.7
In 2005, an expert working group, the Remission
in Schizophrenia Working Group, published the
first consensus-based operational criteria for re-
mission in schizophrenia, based on core symp-
toms and disease duration.8 On the positive and
negative symptoms scale (PANSS),9 an absolute
threshold score (with no single item scoring above
mild) for eight diagnostically relevant core symp-
toms (delusions, unusual thought content, hal-
lucinatory behavior, conceptual disorganization,
mannerisms/posturing, blunted affect, passive/
apathetic social withdrawal, and lack of sponta-
neity and flow of conversation) was required to
persist for 6 months to meet remission criteria.
Subsequent studies have supported the observa-
tion that consensus-based remission criteria can
identify patients with better cognitive function,10,11
functional outcome,11 better quality of life,11–14
lower relapse rate,15 better attitude about drugs,15
and insight.16
A 6-month follow-up as the required duration
for remission could limit its application in clini-
cal practice or short-term research in the identifi-
cation of patients who achieve early remission.
Resolution is defined as the achievement of the
severity component of the remission criteria (si-
multaneous ratings of mild or less on eight of the
PANSS items that evaluate core symptoms) with-
out meeting the duration criterion. Peuskens et al
found significant correlations between the eight
core items and other PANSS items, thus indicating
that the resolution criteria are a useful and clini-
cally meaningful measure to evaluate treatment
outcome in acute psychosis.17 Using the resolution
criteria, the average rate of resolution was approx-
imately one-third in previous reports of Caucasian
patients with schizophrenia.11,17–19
Reports from other ethnic groups have been
limited. Therefore, the aim of this study was to as-
sess the rate of resolution in a group of Chinese
patients with a diagnosis of schizophrenia at 
1 month post-discharge from an acute ward, and
to investigate factors associated with symptom
resolution. In addition to ratings of clinical symp-
toms and side effects, assessments on the Global
Assessment of Functioning (GAF) and Subjective
Well-being under Neuroleptics (SWN) scales, and
Test for Attentional Performance20 (for both visual
and acoustic attention) were also performed. At-
tention deficits are regarded as a stable trait marker
in schizophrenia.21–25
Material and Methods
Study objective and patients
The study was a cross-sectional survey to investi-
gate the resolution rate in Chinese patients with
schizophrenia. Patients were discharged from an
acute psychiatric ward of a Taiwan medical cen-
ter and followed-up at 1 month after their last
psychiatric hospitalization. The inclusion criteria
were: (1) psychiatric diagnosis of schizophrenia,
based on the Diagnostic and Statistical Manual
of Mental Disorders;26 (2) aged 21–65 years; (3)
no major medical history such as traumatic or
cerebrovascular brain insults or thyroid problems;
(4) no significant history of alcohol or substance
abuse; and (5) no comorbidity with dementia or
mental retardation (IQ test > 70). Schizophreni-
form and schizoaffective disorders were not 
included in the present study. The study was per-
formed in accordance with the Declaration of
Helsinki and was approved by the Ethics Review
Committee of Taipei Veterans General Hospital,
Taiwan. The study was described comprehensively
to all patients prior to their enrollment, and all
patients provided written informed consent be-
fore they were allowed to participate.
Assessments
The subjects received clinical assessments includ-
ing the Chinese version of the PANSS,9,27 Udvalg
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for Kliniske Undersøgelser (UKU) Side Effect Rat-
ing Scale,28 Abnormal Involuntary Movements
Scale29 and Simpson Angus Scale (SAS)30 by
trained and experienced psychiatrists. Functional
outcome and quality of life were assessed by 
the Medical Outcomes Study Short-Form 12 (SF-
12),31 GAF,26 and SWN scales.32 The resolution
criteria were that patients achieved ratings of
mild or less on the following eight items in the
PANSS: delusions, unusual thought content, hal-
lucinatory behavior, conceptual disorganization,
mannerisms/posturing, blunted affect, passive/
apathetic social withdrawal and lack of spon-
taneity and flow of conversation.8,17 All raters
participating in the present study were board-
certificated psychiatrists.
To evaluate metabolic side effects, the patients
received anthropometric (body weight, height,
waist, and blood pressure) and biochemical
measurements.
Attention performance was assessed by the
divided attention and go/no-go tasks (Test for
Attentional Performance computerized version
1.5 version; Psytest Press, Freiburg, Germany).20
Divided attention was assessed by simultaneous
visual (detection of a square among crosses) and
auditory (detection of irregularities in a sequence
of tones) discrimination tasks. The go stimulus
consisted of the multiplication symbol ×, whereas
the no-go stimulus was the plus symbol +. Sub-
jects were asked to respond as quickly as possible
after the × symbol appeared. They were not to
press the key if the + symbol appeared. During
the testing process, subjects were seated in a com-
fortable chair with arm rests. The tasks were gen-
erated on a 12.5-inch computer screen (32 cm
diagonal screen length), with a viewing distance
of 60 cm. Subjects were asked to press a key in
the front center of the keyboard with their right
index finger as quickly as possible according to
the given testing instructions. To ensure that the
subjects understood each task, they completed
pretest trials. After subjects completed the pretest
with all correct responses, the formal test was 
administered to record their reaction times,
omissions, and false alarms.
Statistical analysis
Statistical analysis was performed by using SPSS
version 11.5 (SPSS Inc, Chicago, IL, USA). One-
way analysis of variance (or Student’s t test) and
χ2 test were applied to compare the continuous
and categorical variables among groups. Fisher’s
least significant difference tests were used for
post hoc analysis. Pearson’s correlation test (two-
tailed) was chosen to examine the relationship
between clinical variables (such as scores of UKU,
SAS, SWN, and GAF). Multiple logistic regression
analysis was used to determine the variables 
associated with symptomatic resolution among
patients with schizophrenia. Statistical significance
was defined as p < 0.05.
Results
A total of 102 patients met the eligibility criteria
and 90 (88%) agreed to participate in the study.
Forty-six patients (51.1%) were male. The aver-
age age was 38.2 ± 9.4 years, the age at onset of
schizophrenia (occurrence of active psychotic
symptoms) was 23.9 ± 7.3 years, the duration of
illness was 14.3 ± 9.9 years, the number of previ-
ous hospitalizations was 5.7 ± 5.6, and the aver-
age length of the last hospitalization was 35.5 ±
11.5 days. Thirty-three patients (36.7%) met the
symptom remission/resolution criteria (resolu-
tion group). We compared the psychopathology,
side effects, metabolic safety, attention tests, and
quality of life between the resolution and non-
resolution groups.
The resolution group had a significantly higher
level of education (p = 0.024) than the non-
resolution group, but there were no significant
differences for other demographic variables or
chlorpromazine equivalent dosage (Table 1). The
resolution group did have lower scores for the
eight core items of the resolution criteria, and
also had lower scores for other PANSS items than
did the non-resolution group (Figure). The reso-
lution group also showed significantly lower scores
for PANSS total score (p < 0.001), PANSS positive
score (p<0.001), PANSS negative score (p<0.001),
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PANSS general psychopathology score (p< 0.001),
UKU score (p = 0.003), and SAS score (p = 0.019).
For the UKU subscales, the most significant differ-
ences between the resolution and non-resolution
groups were on the items for concentration diffi-
culty (p = 0.02), increased fatigability (p = 0.04),
emotional indifference (p < 0.01), and hypokine-
sia/akinesia (p < 0.01). The resolution group also
demonstrated higher scores for the GAF and SWN
scales (p< 0.05), but not for quality of life (SF-12)
(Table 1). The prevalence of metabolic syndrome
(National Cholesterol Education Program Adult
Treatment Panel III criteria) for the total sample
was 25.3% (22/90). There was no significant dif-
ference in metabolic safety between the resolu-
tion and non-resolution patients (Tables 1 and 2).
Table 1. Comparison of demographic data and metabolic profiles between resolution and non-resolution
groups
Resolution group Non-resolution group
p
(n = 33) (n = 57)
Sex, male (%) 45.5 54.3 NS
Age (yr) 37.5 ± 10.7 38.6 ± 8.6 NS
Married (%) 21.2 12.5 NS
Educational level (yr) 13.4 ± 2.4 12.2 ± 2.5 0.024†
Age of onset (yr) 23.2 ± 5.5 24.3 ± 8.2 NS
Illness duration (yr) 13.6 ± 10.0 14.7 ± 10.0 NS
Previous hospitalizations (n) 4.5 ± 3.9 6.3 ± 6.4 NS
Duration of last admission (d) 32.5 ± 11.2 37.3 ± 11.3 NS
Chlorpromazine equivalent dose (mg/day) 370.0 ± 196.8 458.6 ± 280.4 NS
PANSS total score 48.8 ± 8.4 72.8 ± 15.7 < 0.001§
Positive score 10.5 ± 2.5 18.0 ± 5.4 < 0.001§
Negative score 12.7 ± 3.2 20.3 ± 5.8 < 0.001§
General score 25.5 ± 5.7 34.6 ± 8.2 < 0.001§
UKU score (side effects) 5.1 ± 3.0 7.7 ± 3.7 0.003‡
SAS score (EPS) 2.4 ± 3.1 4.9 ± 4.8 0.009‡
AIMS score (TD) 0.9 ± 2.5 1.3 ± 3.3 NS
GAF scores (function) 59.5 ± 9.5 46.9 ± 10.5 < 0.001§
SF-12_PCS (QoL) 34.6 ± 20.4 41.2 ± 16.7 NS
SF-12_MCS (QoL) 31.3 ± 19.2 33.9 ± 16.1 NS
SWN scores (well-being) 78.4 ± 13.6 72.2 ± 13.6 0.047†
Waist (cm) 34.2 ± 5.4 34.1 ± 4.6 NS
Triglyceride (mmol/L) 165.8 ± 138.8 148.7 ± 142.4 NS
High density lipoproteins (mg/dL) 51.3 ± 15.3 52.8 ± 16.9 NS
Glucose (mg/dL) 90.2 ± 15.2 91.1 ± 13.9 NS
Systolic BP (mmHg) 116.3 ± 18.9 119.3 ± 16.3 NS
Diastolic BP (mmHg) 72.6 ± 11.9 73.9 ± 11.5 NS
*Data presented as n or mean ± standard deviation. †p < 0.05; ‡p < 0.01; §p < 0.001. NS = Not significant; PANSS = Positive and
Negative Symptoms Scale; UKU = Udvalg for Kliniske Undersogelser Side Effect Rating Scale; SAS = Simpson Angus Scale;
AIMS = Abnormal Involuntary Movements Scale; SF-12_PCS = Short Form-12 Physical Health Component Score; SF-12_MCS = Short
Form-12 Mental Health Component Score; GAF = Global Assessment of Functioning; SWN = Subjective Well-being under Neuroleptics
Scale; QoL = quality of life; EPS = extrapyramidal symptom; BP = blood pressure.
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There were also no significant differences for 
attention performance (divided attention and
go/no-go tests).
Correlation analysis showed a positive corre-
lation between the scores on UKU and SAS (r =
0.327, p = 0.005). We conducted multiple regres-
sion analyses with SAS and UKU separately. The
UKU score was the most significant in relation to
symptom remission (odds ratio, 0.788; 95% con-
fidence interval, 0.632–0.983), after controlling
for age, sex, duration of illness, education, duration
of index hospitalization, and antipsychotic dosage
(chlorpromazine equivalent dosage) (Table 3).
The SAS was not significantly related to sympto-
matic remission after other factors were controlled.
Antipsychotics and resolution
Among the 90 patients, 13 (14.4%) received clo-
zapine, 51 (56.7%) received other second genera-
tion antipsychotics (SGAs), including ziprasidone
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Figure. Detailed Positive and Negative Syndrome Scale scores between resolution and non-resolution groups. Mean ±
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(2 patients), quetiapine (4 patients), zotepine 
(3 patients), olanzapine (8 patients), risperidone
(22 patients), amisulpiride (7 patients) and arip-
iprazole (5 patients). Eleven patients (12.2%) 
received first generation antipsychotics (FGAs)
alone, and 12 (13.3%) received combinations of
FGAs and SGAs. The prescribed antipsychotics
for the other three patients cannot be ascertained
because they participated in another therapeutic
drug trial during and after their hospitalization.
To investigate the effect of antipsychotics on reso-
lution, the subjects were divided into four groups:
clozapine (n = 13), SGA (n = 51), FGA (n = 11)
and combination (CB; n = 12). Using standard
guidelines, doses of all the antipsychotics were
converted to chlorpromazine equivalent doses
for further comparisons.33 The average doses of
antipsychotics in the CB group were higher than
those in the SGA and clozapine groups, and the
patients on FGAs were prescribed higher doses
than were those on SGAs (Table 4). The clozap-
ine and CB groups showed significantly more 
severe psychopathology in terms of PANSS total
score (p < 0.001), positive symptoms (p = 0.013),
and general psychopathology (p = 0.002), as well
as a lower resolution rate than the FGA and 
SGA groups (p = 0.032). For safety and other out-
come profiles, the clozapine and CB groups also
showed higher UKU (p < 0.001) and lower GAF
(p = 0.009) and SWN (p = 0.002) scores than did
the FGA and SGA groups. The prevalence rate of
metabolic syndrome in the clozapine and CB
groups was 38.5% and 41.5%, respectively, com-
pared with 17.6% and 30% in the SGA and FGA
Table 2. Comparison of attention test between resolution and non-resolution groups*
Resolution group (n = 33) Non-resolution group (n = 57) p
Divided attention task (sec)
Mean RT 857.7 ± 206.1 840.0 ± 195.5 NS
SD of RT 208.1 ± 82.6 213.9 ± 60.2 NS
Omission 7.5 ± 7.4 6.1 ± 6.8 NS
False alarm 0.7 ± 1.0 1.9 ± 7.2 NS
Go/no-go task (sec)
Mean RT 509.3 ± 98.9 495.2 ± 123.8 NS
SD of RT 96.9 ± 50.4 92.2 ± 39.2 NS
Omission 1.6 ± 3.8 0.2 ± 0.5 NS
False alarm 1.4 ± 3.2 1.2 ± 1.6 NS
*Data presented as mean ± standard deviation. RT = Reaction time; SD = standard deviation; NS = not significant.
Table 3. Multiple logistic regression for predictors of symptom resolution among patients with schizophrenia*
Resolution group Non-resolution group
Odds ratio 95% CI p
(n = 33) (n = 57)
Sex, male 15 (45.5) 31 (54.3) 2.163 0.612–7.640 NS
Age (yr) 37.5 ± 10.7 38.6 ± 8.6 0.969 0.894–1.050 NS
Educational level (yr) 13.4 ± 2.4 12.2 ± 2.5 1.163 0.896–1.511 NS
Illness duration (yr) 13.6 ± 10.0 14.7 ± 10.0 0.995 0.923–1.072 NS
Duration of last admission (d) 32.5 ± 11.2 37.3 ± 11.3 1.002 0.947–1.060 NS
Chlorpromazine equivalent 370.0 ± 196.8 458.6 ± 280.4 1.002 0.999–1.005 NS
dose (mg/day)
UKU score (side effects) 5.1 ± 3.0 7.7 ± 3.7 0.788 0.632–0.983 0.035†
SWN score (well-being) 78.4 ± 13.6 72.2 ± 13.6 0.990 0.942–1.040 NS
*Data presented as n (%) or mean ± standard deviation; †p < 0.05. CI = Confidence interval; NS = not significant; UKU = Udvalg Kliniske
Undersøgelser Side Effect Rating Scale; SWN = Subjective Well-being under Neuroleptics Scale.
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groups, respectively. The difference was not statis-
tically significant.
Discussion
Our study is believed to be the first Chinese re-
port of cross-sectional symptom resolution rate
in schizophrenia using the criteria of the Remis-
sion in Schizophrenia Working Group. Although
ethnicity has been reported to have an impact on
antipsychotic treatment outcome,34 sociocultural
factors can influence that outcome directly or in-
directly.35 Our results showed a 36.7% resolution
rate among our schizophrenia patients. This re-
sult is similar to the 21–44.8% reported in previ-
ous Caucasian studies.11,17,18,36 We also found that
patients with fewer general side effects had a
higher rate of remission (symptom resolution cri-
teria), which is also consistent with previous re-
ports.37–40 However, most of the previous results
have come from cross-sectional screening in com-
munity outpatients with or without antipsychotic
treatment.11,19 Our sample consisted of patients
at 1 month after discharge from inpatient care, and
these patients might have had better drug com-
pliance or symptomatic stability when compared
with those in previous studies. More studies in
Chinese outpatient or community settings are re-
quired to compare the rate of symptom resolution
with that in Caucasian patients.
Similar to the study of Docherty et al,13 all the
subscales in PANSS, including positive, negative
and general psychopathology, showed significantly
lower scores in patients who met the resolution
criteria. These suggest that the eight core items of
PANSS resolution criteria represent the global se-
verity of psychopathology. The consensus-based
operational criteria adopted distinct thresholds,
provided that the severity of three major psy-
chotic symptom dimensions (psychoticism, neg-
ative symptoms, and disorganization) was mild
or better.8 The absolute thresholds could be more
meaningful in identifying patients in an asymp-
tomatic status, when compared with relative
thresholds such as a 25–50% reduction from the
baseline rating scores.41 There are still divergent
uses of the consensus-based remission criteria.8
Some researchers have used the term remission,
but resolution criteria for cross-sectional symp-
tom remission were applied in their studies.11,23,36
There could be a related clinical problem in using
the 6-month duration requirement, because poor
insight and drug compliance are common in
schizophrenia.20–23 Our findings support the
study of Peuskens et al that the resolution criteria
were an easy, useful, and clinically meaningful as-
sessment to identify early symptom remission of
schizophrenia in acute treatment or short-term
clinical trials,17 and they can identify patients
with better global function and subjective well-
being. Moreover, a 1-year follow-up study has in-
dicated that early remission is a good predictor
for long-term remission.42
Our study also supported the observation that
resolution patients not only had less severe psy-
chopathology, but had better global function and
subjective well-being as well. Furthermore, our
multivariate regression model showed that reso-
lution patients had fewer side effects as measured
by UKU. These included difficulty in concentra-
tion, increased fatigability, emotional indifference,
hypokinesia/akinesia and extrapyramidal symp-
toms after controlling for other factors including
age, sex, duration of illness, education, duration of
index hospitalization, and antipsychotic dosage
(chlorpromazine equivalent dosage). Tolerance to
antipsychotics has been a focus of research and is
believed to influence patients’ drug compliance,
discontinuation rate, and global outcome.37–40
Although SGA drugs were once thought to be
better than FGAs, mounting evidence has shown
that they are not a homogeneous class and differ in
many properties such as efficacy and tolerance.41
Our study supports the notion that tolerance is
an important factor associated with remission/
resolution in schizophrenia. Patients on cloza-
pine or combinations of FGAs and SGAs had
more severe psychopathology and side effects,
and showed a significantly lower resolution rate
than did patients treated with FGAs or SGAs alone
(p = 0.032). There were no significant differences
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in the PANSS score, side effects, and resolution
rate between the SGA and FGA groups in this
study. However, due to the methodological limi-
tations of the cross-sectional design, the results
should not be used to support any claim that
FGA drugs have comparable efficacy to SGAs,
even though some meta-analyses have indicated
no significant advantages in measurements of ef-
ficacy or tolerance for SGAs over moderate daily
doses of FGAs.40,43,44 In the present study, the
lower resolution rate in the clozapine or CB groups
may have resulted from different baseline char-
acteristics of patient populations; for example,
patients with more severe psychotic symptoms
might have been prescribed clozapine, antipsy-
chotic combinations, or SGAs, so that lower rates
in achieving symptomatic resolution were found
among them. On the other hand, half the schiz-
ophrenia patients were well controlled by FGAs
alone, with comparable tolerance to that of SGAs
alone, even with higher average doses (586.4 ±
300.1 vs. 319.4 ± 152.8 mg/day, Table 4). Although
a causal relationship between tolerance and symp-
tom remission cannot be determined by this cross-
sectional study, our findings support the premise
that selection of an antipsychotic for any one pa-
tient should be on an individual basis, and indi-
vidualized treatment taking into consideration
efficacy and side effects could be important.
Previous reports on Caucasian patients have
shown better quality of life, social function,11,13,14
and cognitive function in patients in remis-
sion.10,11,16 In our study, however, the resolution
patients did not showed better quality of life (SF-
12) or attention performance, but they did show
better GAF and subjective well-being than the
non-resolution patients. One possible explana-
tion is that GAF score and subjective well-being
represent present functional outcome, but im-
provement in quality of life and attention might
take longer to achieve, especially in chronic pa-
tients. Van Os et al also observed that quality-of-
life outcomes are less sensitive than GAF score.45
A 1-year follow-up study in patients with base-
line remission has also shown that around 90%
of patients had further improvement on mental
health component scores of SF-12.42 It seems
that improvement in quality of life is more time-
dependent than global function, and patients
with longer symptom remission have a better
chance of moving forward to a life of higher
quality. Deficit in attention performance has
been regarded as a possible trait marker or en-
dophenotype in schizophrenia, because patients
have shown a lack of improvement in attention
during symptom remission.21–25 Similar to our
findings, Liu et al found that schizophrenia pa-
tients who respond to risperidone or haloperidol
after 12 weeks treatment do not show an im-
provement in attention deficit.25 However, some
longitudinal studies have indicated that cognitive
function improves gradually in those who are con-
trolled by continuous use of antipsychotics.42,46,47
This suggests that cognitive function is also a
more distal outcome measurement, at least in a
subgroup of patients who respond well to pre-
scribed antipsychotics.
The interpretation of our findings needs to be
tempered by several limitations of the study.
First, the total sample size was relatively small,
and the choice of antipsychotic depended on the
decision of the physician in charge. The outcome
differences among different treatment groups still
need to be confirmed by large-sample studies or
randomized trials. Second, all the subjects came
from a single hospital, and results might not gen-
eralize to all Taiwanese schizophrenia patients,
although we did recruit our patients from those
with first episodes as well as chronic disease, and
they ranged widely in age and duration of illness.
Finally, attention and executive performance are
only part of cognitive function and other param-
eters should be tested. Further larger studies from
different ethnic groups are recommended.
In conclusion, our study suggested a one-third
resolution rate in Chinese patients with schizo-
phrenia, which was consistent with previous re-
ports for Caucasian patients. Resolution criteria
based on eight core items of PANSS are an easy
and practical measurement of symptom remission,
or for short-term studies to identify patients with
stable psychopathology, better global function
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and subjective well-being; however, they are less
sensitive to quality of life and social and cogni-
tive function. The patients in symptom remis-
sion had a higher tolerance for antipsychotics than
those who were not. Results showed an individu-
alized response and tolerance to antipsychotics,
and that some patients could be well controlled
by FGAs without prominent side effects. Further
larger studies looking at different ethnic groups
are recommended.
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